EXUMA Biotech
Gregory Schreiber currently serves as VP of IP Strategy & Licensing at EXUMA Biotech, where responsibilities include shaping technology and legal strategies for novel gene and cell therapies aimed at treating cancer and autoimmune disorders. Previous experience includes a role as Senior Director of Academic Alliances & Technology Licensing at Intrexon Corporation, contributing to the development of biologically-based products. Earlier in their career, Gregory held the position of Associate Director of Corporate Development at Life Technologies and also served as Associate Director at Johns Hopkins Technology Transfer. Gregory Schreiber earned a Ph.D. in Immunology from Washington University in St. Louis and holds a degree from the University of California, Berkeley.
This person is not in any teams
EXUMA Biotech
EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market CAR-T therapies for the treatment of cancer. Founded in 2015, the company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and across the US with sites in West Palm Beach and San Diego.